Search results for "Lymphoblastic leukemia"

showing 10 items of 85 documents

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

2002

The feasibility of nonmyeloablative stem cell transplantation (NST) was evaluated in 22 adults with high-risk ALL. 16/22 patients had advanced disease and 11/22 had Ph+ ALL. Eleven patients received NST as first stem cell transplantation (SCT). Eleven patients had relapses after allogeneic or autologous SCT and underwent a salvage NST. 18/22 patients (82%) engrafted after NST. 13/16 patients (81%) with active disease reached complete remission (CR). 11 of 13 patients developed GVHD. After first NST 10/11 patients (91%) engrafted. Six of seven patients with active disease reached CR. Three of five relapsing patients reached subsequent CR after donor lymphocyte infusions, termination of immun…

AdultMaleRiskMelphalanCancer Researchmedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentSalvage therapyGraft vs Leukemia EffectPilot ProjectsAcute lymphocytic leukemiamedicineHumansPhiladelphia ChromosomeSurvival rateSalvage TherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationImmunosuppressionHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryFludarabineSurvival RateTransplantationsurgical procedures operativeOncologyDisease ProgressionFeasibility StudiesFemalebusinessmedicine.drugLeukemia
researchProduct

Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therap…

2002

In acute lymphoblastic leukemia (ALL), treatment with granulocyte colony stimulating factor (G-CSF) during remission induction shortens granulocytopenia and may decrease morbidity due to infections. However, the optimal timing of G-CSF administration after chemotherapy is not known. In a prospective randomized multi-center study, adult ALL patients were treated with high-dose ARA-C [HDAC, 3 g/m(2) bid (1 g/m(2) bid for T-ALL) days 1-4] and mitoxantrone (MI 10 mg/m(2) days 3-5). They were randomized to receive recombinant human G-CSF (Lenograstim) 263 micro g/day SC starting either from day 12 (Group 1) or day 17 (Group 2). Fifty-five patients (41 male, 14 female) with a median age of 34 yea…

AdultMalemedicine.medical_specialtyNeutropeniaAdolescentHematopoietic growth factormedicine.medical_treatmentOpportunistic InfectionsNeutropeniaGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansProspective StudiesChemotherapyMitoxantroneHematologybusiness.industryCytarabineHematologyGeneral MedicineMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHematopoiesisSurgeryGranulocyte colony-stimulating factorLenograstimTreatment OutcomeFemalebusinessmedicine.drugAnnals of Hematology
researchProduct

ACUTE VISION LOSS AS THE ONLY SIGN OF LEUKEMIA RELAPSE.

2016

Purpose To report a case of unilateral exudative retinal detachment as the sole presentation of relapsing B-type lymphoblastic leukemia in a 35-year-old man after 3 years of remission. Methods Case report. Results A 35-year-old man in complete remission of high-risk type B acute lymphoblastic leukemia (ALL-B) presented with acute vision loss in his left eye. Exudative retinal detachment was diagnosed at initial evaluation. Hematological and ocular studies were performed. Although there was no evidence of blood, cerebrospinal fluid, or bone marrow disease relapse, transvitreal retinochoroidal cytology identified the infiltration of lymphoblastic leukemic B cells with t(12:21) translocation a…

AdultMalemedicine.medical_specialtyVisual acuitymedicine.medical_treatmentBiopsyVisual AcuityVitrectomyAntineoplastic AgentsEndotamponadeBlindnessGastroenterology03 medical and health sciences0302 clinical medicineCerebrospinal fluidRecurrencehemic and lymphatic diseasesInternal medicineCytologyPrecursor B-Cell Lymphoblastic Leukemia-LymphomaVitrectomyBiopsymedicineHumansSilicone OilsB Acute Lymphoblastic Leukemiamedicine.diagnostic_testbusiness.industryRetinal DetachmentMagnetic resonance imagingGeneral MedicineExudative retinal detachmentFlow CytometryMagnetic Resonance ImagingOphthalmology030220 oncology & carcinogenesisAcute Disease030221 ophthalmology & optometrymedicine.symptomInjections IntraocularbusinessRetinal casesbrief reports
researchProduct

Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population‐bas…

2021

Objective: Investigate all-cause and cause-specific late mortality after childhood acute lymphoblastic leukemia (ALL) in a population-based Nordic cohort. Methods: From the cancer registries of Denmark, Finland, and Sweden, we identified 3765 five-year survivors of ALL, diagnosed before age 20 during 1971–2008. For each survivor, up to five matched comparison subjects were randomly selected from the general population (n = 18,323). Causes of death were classified as relapse related, health related, and external. Late mortality was evaluated by cumulative incidences of death from 5-year survival date. Mortality hazard ratios (HR) were evaluated with Cox proportional models. Results: Among th…

AdultPediatricsmedicine.medical_specialtycause-specific mortalityDenmarkPopulationlong-term follow-upacute lymphoblastic leukemiaDECADESCohort StudiesYoung AdultCancer SurvivorsSurvivorship curvechildhood cancerHumansMedicineCumulative incidenceeducationChildhood Acute Lymphoblastic LeukemiaFinlandSwedeneducation.field_of_studyOvertreatmentbusiness.industryHazard ratioDEATHCancer5-YEAR SURVIVORSHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCANCERConfidence intervalREDUCTIONOncologylate mortalityPediatrics Perinatology and Child HealthCohortFOLLOW-UPbusinesssurvivorshipPediatric Blood & Cancer
researchProduct

Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies

2019

Ceftolozane-tazobactam (C/T), a novel fifth-generation cephalosporin/β-lactamase inhibitor combination active against multidrug-resistant (MDR) Pseudomonas aeruginosa, is currently approved by the U.S. Food and Drug Administration (FDA) to treat complicated intra-abdominal and urinary tract

Adultmedicine.medical_specialtymedicine.drug_classCritical IllnessUrinary systemCephalosporinHemodiafiltrationMicrobial Sensitivity TestsOff-label usemedicine.disease_causeExtracorporealPharmacokineticspolycyclic compoundsmedicineHumansPseudomonas InfectionsPharmacology (medical)Intensive care medicineLetter to the EditorPharmacologyCritically illbusiness.industryPseudomonas aeruginosaPrecursor Cell Lymphoblastic Leukemia-Lymphomabacterial infections and mycosesAnti-Bacterial AgentsCephalosporinsInfectious DiseasesPseudomonas aeruginosaFemaleCeftolozanebusinessAntimicrobial Agents and Chemotherapy
researchProduct

Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia

2002

Background Antimetabolite-based continuation therapy is commonly used for childhood acute lymphoblastic leukemia (ALL) and hypoglycemia after prolonged fasting has been recently reported. We have found that spontaneous, symptomatic hypoglycemia (SH) may also occur in such patients. Procedure Between 1995 and 1999, patients treated according to the AIEOP-ALL-95 study received BFM-type intensive chemotherapy; mercaptopurine (6-MP) was given (60 mg/m2/days, orally for 14 days) during the second part of induction and during consolidation therapy (25 mg/m2/day, orally for 8 weeks); thioguanine (6-TG) was given during reinduction therapy with protocol II (60 mg/m2/day, orally for 14 days); contin…

Cancer ResearchChemotherapyVincristinemedicine.medical_specialtymedicine.drug_classbusiness.industrymedicine.medical_treatmentHypoglycemiamedicine.diseaseGastroenterologyMercaptopurineAntimetaboliteSurgeryTioguanineOncologyAcute lymphocytic leukemiaInternal medicinePediatrics Perinatology and Child HealthmedicinebusinessChildhood Acute Lymphoblastic Leukemiamedicine.drugMedical and Pediatric Oncology
researchProduct

Immune Therapy of Lympho-Hemopoietic Malignancies.

2017

Cancer ResearchImmunoconjugatesbusiness.industryAntibodies MonoclonalHematologyPrecursor Cell Lymphoblastic Leukemia-LymphomaImmune therapy03 medical and health sciencesHaematopoiesis0302 clinical medicineTreatment OutcomeOncologyLeukemia Myeloid030220 oncology & carcinogenesisHematologic NeoplasmsImmunologyAcute DiseaseMedicineHumans030212 general & internal medicineImmunotherapybusinessOncology research and treatment
researchProduct

Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic proge…

2001

Stromal cell-derived factor-1alpha (SDF-1alpha) is a potent chemoattractant for hematopoietic progenitor cells (HPC), suggesting that it could play an important role during their migration within or to the bone marrow (BM). The integrin VLA-4 mediates HPC adhesion to BM stroma by interacting with CS-1/fibronectin and VCAM-1. It is required during hematopoiesis and homing of HPC to the BM. As HPC migration in response to SDF-1alpha might require dynamic regulation of integrin function, we investigated if SDF-1alpha could modulate VLA-4 function on BM CD34(hi) cells.CD34(hi) BM cells and hematopoietic cell lines were tested for the effect of SDF-1alpha on VLA-4-dependent adhesion to CS-1/fibr…

Cancer ResearchIntegrinsReceptors CXCR4Stromal cellIntegrinCD34Receptors Lymphocyte HomingVascular Cell Adhesion Molecule-1Bone Marrow CellsIntegrin alpha4beta1Hematopoietic Cell Growth FactorsCell LineColony-Forming Units Assaychemistry.chemical_compoundMiceLeukemia Megakaryoblastic AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaGeneticsCell AdhesionTumor Cells CulturedAnimalsHumansVCAM-1Cell adhesionMolecular BiologybiologyChemotaxisVLA-4Antibodies MonoclonalCell BiologyHematologyHematopoietic Stem CellsChemokine CXCL12Peptide FragmentsRecombinant ProteinsCell biologyFibronectinsFibronectinchemistryLiverbiology.proteinStromal CellsChemokines CXCHoming (hematopoietic)Signal TransductionExperimental hematology
researchProduct

Early deaths in acute lymphoblastic leukemia (ALL): results of the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (AIL-AIEOP).

1984

In this retrospective multicentric study, we report on early deaths (ie, those that occurred during the first month of treatment) in a total of 943 newly diagnosed ALL pediatric patients registered from 1976 to 1981 at 21 centers of the AIL-AIEOP. Objectives of this study were as follows: (1) to verify the incidence and the cause of early death in a wide population of children with ALL and (2) to elucidate factors associated with early death and therefore to identify “high-risk” groups of patients. Out of the 943 ALL patients, 39 (4.1%) early deaths were registered. Main causes were infection, 20 patients (51.3%); hemorrhage, 11 patients (28.3%); uric acid nephropathy, 2 patients (5.1%); ca…

Cancer ResearchPediatricsmedicine.medical_specialtyAdolescentHeart DiseasesLymphoblastic LeukemiaPopulationEarly deathHemorrhageInfectionsMediastinal NeoplasmsNephropathyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationChildRetrospective Studieseducation.field_of_studyAcute leukemiabusiness.industryIncidence (epidemiology)Age FactorsMediastinumInfantmedicine.diseasePrognosisLeukemia Lymphoidmedicine.anatomical_structureOncologyChild PreschoolPediatrics Perinatology and Child HealthSyndrome of inappropriate antidiuretic hormone secretionKidney DiseasesbusinessMedical and pediatric oncology
researchProduct

Atopic disease and childhood acute lymphoblastic leukemia

2003

Our objective was to test the hypothesis that the risk of childhood leukemia is associated with allergies or a family history of allergy. We used a German population-based case-control study with self-reported information on allergies of the children and their first-degree relatives. Our study included a total of 1,130 cases of acute lymphoblastic leukemia (ALL), 164 cases of acute myeloid leukemia (AML) and 2,957 controls. A major finding of our study is that hay fever, neurodermatitis and contact eczema are underrepresented within the group of children with ALL, with respective odds ratios (OR) of 0.45 (95% confidence interval [CI] 0.31-0.66) for hay fever, of 0.49 (CI 0.34-0.71) for neur…

Cancer ResearchPediatricsmedicine.medical_specialtyAllergyChildhood leukemiabusiness.industrymedicine.diseaseAtopyOncologyAcute lymphocytic leukemiamedicineHay feverRisk factorNeurodermatitisbusinessChildhood Acute Lymphoblastic LeukemiaInternational Journal of Cancer
researchProduct